Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Apr;1(2):182-8.
doi: 10.1602/neurorx.1.2.182.

Biomarkers: potential uses and limitations

Richard Mayeux  1
Affiliations
Review

Biomarkers: potential uses and limitations

Richard Mayeux. NeuroRx. 2004 Apr.

Abstract

Biomarkers provide a dynamic and powerful approach to understanding the spectrum of neurological disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis and prognosis. Defined as alterations in the constituents of tissues or body fluids, these markers offer the means for homogeneous classification of a disease and risk factors, and the can extend our base information about the underlying pathogenesis of disease. Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. This brief review describes the major uses of biomarkers in clinical investigation. Careful assessment of the validity of biomarkers is required with respect to the stage of disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory. Issues that affect the analysis of biomarkers are discussed along with recommendations on how to deal with bias and confounding.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Disease pathway and potential impact of biomarkers.
See this image and copyright information in PMC

References

    1. Hulka BS. Overview of biological markers. In: Biological markers in epidemiology (Hulka BS, Griffith JD, Wilcosky TC, eds), pp 3–15. New York: Oxford University Press, 1990.
    1. Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 3: 525–529, 2003. - PubMed
    1. Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis 21: 517–524, 2000. - PubMed
    1. Gordis L. Epidemiology and public policy. In: Epidemiology (Gordis L, ed), pp 247–256. Philadelphia: W.B. Saunders, 1996.
    1. Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40: 25–40, 2003. - PubMed

Publication types